Ignite Creation Date:
2025-12-24 @ 2:06 PM
Ignite Modification Date:
2025-12-31 @ 1:15 PM
Study NCT ID:
NCT06960395
Status:
RECRUITING
Last Update Posted:
2025-08-06
First Post:
2025-04-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Vir Biotechnology, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-07-22
Start Date Type:
ACTUAL
Primary Completion Date:
2029-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-08
Completion Date Type:
ESTIMATED
First Submit Date:
2025-04-21
First Submit QC Date:
None
Study First Post Date:
2025-05-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-31
Last Update Post Date:
2025-08-06
Last Update Post Date Type:
ACTUAL